{"id":169196,"date":"2019-09-17T11:46:05","date_gmt":"2019-09-17T11:46:05","guid":{"rendered":"http:\/\/www.georgianewsdesk.com\/news\/story\/169196\/liquid-biopsy-diagnostic-market-the-one-step-diagnostic-test-for-cancer.html"},"modified":"2019-09-17T11:46:05","modified_gmt":"2019-09-17T11:46:05","slug":"liquid-biopsy-diagnostic-market-the-one-step-diagnostic-test-for-cancer","status":"publish","type":"post","link":"http:\/\/www.honolulunewsnow.com\/news\/story\/169196\/liquid-biopsy-diagnostic-market-the-one-step-diagnostic-test-for-cancer.html","title":{"rendered":"Liquid Biopsy Diagnostic Market – The One Step Diagnostic Test for Cancer"},"content":{"rendered":"
\"Liquid<\/a><\/p>\n
\n
As per the report of Stratview Research, it is expected that liquid biopsy will complement SB within the next 3-5 years and will become a tool of choice for dynamic monitoring of patients on treatment or under active surveillance.<\/p>\n

(Image Source: MedTech Insight – Informa PLC)<\/p><\/div>\n<\/div>\n<\/div>\n

Stratview Research has published a report on Liquid Biopsy Diagnostic Market after validating their internal database and offers insights into the current market as well as the future of the Liquid Biopsy Diagnosis. <\/div>\n

Stratview Research has published a report on Liquid Biopsy Diagnostic Market<\/a> that studies the global liquid biopsy market over the trend period of 2014 to 2017 and the forecast period of 2018 to 2025.<\/p>\n

Get a free sample here:<\/strong> https:\/\/www.stratviewresearch.com\/Request-Sample\/422\/liquid-biopsy-diagnostic-market.html<\/a><\/p>\n

The World Health Organisation mentioned in 2017 that the number of breast cancer deaths around the globe is expected to increase and more than 991,000 women are expected to die annually of breast cancer across the globe by 2040.<\/p>\n

Liquid biopsy is capable of early detection of cancer and this can have a potential impact on several product lines, mainly critical illness (CI) and medical insurance. Over time, these product lines have seen several innovations and have come up with different categories such as stages CI, multi-pay, and cancer-only plans. The benefit of these products is that they cover early-stage cancers as well. Increased near-term utilization of liquid biopsy as part of routine screening tests or diagnostic protocols could lead to higher cancer incidence rates than anticipated that could impact the pricing assumptions of certain products, especially those offering early-stage cancer benefits.<\/p>\n

Request for the Table of Contents here:<\/strong> https:\/\/www.stratviewresearch.com\/toc\/422\/liquid-biopsy-diagnostic-market.html<\/a><\/p>\n

The liquid biopsy (LB) concept complements the personalized medicine approach and provides an innovative way for patient selection in clinical trials; here mutational analysis supports patient eligibility for targeted therapy. The ‘one-stop’ diagnostic test of liquid biopsy is currently creating a buzz in the market with the entry of key competitors such as Biocept, Oncocyte, and others.<\/p>\n

The report Liquid Biopsy Diagnostic Market<\/a> published by Stratview Research mentions that in near future it is expected that liquid biopsy will complement SB within the next 3-5 years and will become a tool of choice for dynamic monitoring of patients on treatment or under active surveillance.<\/p>\n

Features of the Report<\/strong><\/p>\n

The report provides detailed insights into the liquid biopsy market size, trends, forecasts, and dynamics to provide a base for the decision-makers to formulate growth strategies in the present market. The report has these salient features:<\/p>\n